Skip to content
Open access

miR-877-5P acts as a tumor suppressor in multiple myeloma by targeting MAPK8: a study on prognostic value and functional mechanism.

Sep 2026 · Hematology · Vol 31 1, pp. 2722564 · 0 citations · 30 references
Medicine

Abstract

Objectives

This study aimed to investigate Investigate the expression level, prognostic value, and biological function of miR-877-5p in MM.

Methods

A total of 103 MM patients and 98 non-tumor controls were included in the study. miR-877-5p expression level was verified by RT-qPCR, and its prognostic value was evaluated through Kaplan-Meier and the Cox regression model. MM cell proliferation and apoptosis were assessed with the CCK‑8 assay and flow cytometry. The potential target genes of miR-877-5p were predicted by bioinformatics analysis and verified by dual luciferase assay. Rescue assays confirmed that MAPK8 mediates the regulatory function of miR-877-5p.

Results

miR-877-5p was reduced in MM, and its low level was associated with a poorer overall survival of patients, being an independent prognosticator of poor survival in MM. Function experiments confirmed that overexpression of miR-877-5p could inhibit the proliferation of MM cells and promote apoptosis. Mechanistically, MAPK8 was a direct downstream target of miR-877-5p. MAPK8 was upregulated in MM and negatively correlated with miR-877-5p levels. Rescue assays were conducted to verify that MAPK8 overexpression reversed the effect of miR-877-5p on MM cell proliferation and apoptosis.

Discussion

These findings indicate that miR-877-5p exerts tumor-suppressive functions in MM, likely through negative regulation of MAPK8. The miR-877-5p/MAPK8 axis may represent a novel regulatory pathway involved in MM progression.

Conclusions

miR-877-5p acts as a tumor suppressor in MM and may serve as a potential biomarker for prognosis assessment. Its regulatory role in MM progression is likely mediated through targeting and inhibiting MAPK8.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.